Featured Research

from universities, journals, and other organizations

Researchers investigate dasatinib in combination with other drugs for advanced, recurrent ovarian cancer

Date:
November 14, 2012
Source:
Moffitt Cancer Center
Summary:
Researchers have conducted a phase I trial of dasatinib, an oral SRC-family tyrosine kinase inhibitor, to determine the maximum tolerated dose when combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer.

Researchers at Moffitt Cancer Center and Duke University Medical Center have conducted a phase I trial of dasatinib, an oral SRC-family tyrosine kinase inhibitor, to determine the maximum tolerated dose when combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer. They found that 150 mg daily in combination with the two other drugs was optimum.

The study appears in the October issue of Clinical Cancer Research, a publication of the American Association for Cancer Research.

Dasatinib has promising potential in treating advanced ovarian cancer because the SRC pathways play a role in the increased activation of cell migration, proliferation, survival, invasion and angiogenesis (tumor blood vessel growth). The SRC pathways have been found to be frequently disregulated in solid tumors and can increase chemotherapy resistance.

Previous laboratory studies have shown that SRC inhibition enhanced the cytotoxic efficacy of both paclitaxel and cisplatin in ovarian cancer cell lines. In vivo studies found that SRC inhibition resulted in decreased tumor growth.

"This is the first study to define the proper dose of dasatinib that, in combination with paclitaxel and carboplatin, can be moved forward into phase II or III studies," said study co-author Robert M. Wenham, M.D., M.S., F.A.C.O.G., F.A.C.S., member of the Center for Women's Oncology and Experimental Therapeutics Program at Moffitt. "Those additional trials may better help us understand not only the tolerability of the combination, but the efficacy in treating cancers."

The study found that administration of dasatinib with paclitaxel did not alter the effects of either drug and that dasatinib may be better used in combination with chemotherapy agents for a synergistic effect.

"It may also be better to combine dasatinib with only one cytotoxic therapy to improve tolerability," Wenham added.

The researchers concluded that finding biomarkers to direct the use of targeted therapies is of the utmost importance. Although SRC gene expression was not correlated with response, the research team found several differentially regulated genes between responders and those with stable disease.

"Unfortunately, a biomarker was unable to be identified to demonstrate which women are most likely to benefit from dasatinib," said study contributor Johnathan M. Lancaster, M.D., Ph.D., chair of Moffitt's Department of Women's Oncology, member of the Experimental Therapeutics Program and president of the Moffitt Medical Group. "Further study should explore relevant biomarkers and identify a patient population most likely to benefit from the addition of dasatinib."


Story Source:

The above story is based on materials provided by Moffitt Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. A. Secord, D. K. Teoh, W. T. Barry, M. Yu, G. Broadwater, L. J. Havrilesky, P. S. Lee, A. Berchuck, J. Lancaster, R. M. Wenham. A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer. Clinical Cancer Research, 2012; 18 (19): 5489 DOI: 10.1158/1078-0432.CCR-12-0507

Cite This Page:

Moffitt Cancer Center. "Researchers investigate dasatinib in combination with other drugs for advanced, recurrent ovarian cancer." ScienceDaily. ScienceDaily, 14 November 2012. <www.sciencedaily.com/releases/2012/11/121114112946.htm>.
Moffitt Cancer Center. (2012, November 14). Researchers investigate dasatinib in combination with other drugs for advanced, recurrent ovarian cancer. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2012/11/121114112946.htm
Moffitt Cancer Center. "Researchers investigate dasatinib in combination with other drugs for advanced, recurrent ovarian cancer." ScienceDaily. www.sciencedaily.com/releases/2012/11/121114112946.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Obama Orders Military Response to Ebola

Obama Orders Military Response to Ebola

AP (Sep. 16, 2014) Calling the Ebola outbreak in West Africa a potential threat to global security, President Barack Obama is ordering 3,000 U.S. military personnel to the stricken region amid worries that the outbreak is spiraling out of control. (Sept. 16) Video provided by AP
Powered by NewsLook.com
UN: 20,000 Could Be Infected With Ebola by Year End

UN: 20,000 Could Be Infected With Ebola by Year End

AFP (Sep. 16, 2014) Nearly $1.0 billion dollars is needed to fight the Ebola outbreak raging in west Africa, the United Nations say, warning that 20,000 could be infected by year end. Duration: 00:40 Video provided by AFP
Powered by NewsLook.com
Obama: Ebola Outbreak Threat to Global Security

Obama: Ebola Outbreak Threat to Global Security

AP (Sep. 16, 2014) President Obama is ordering U.S. military personnel to West Africa to deal with the Ebola outbreak, which is he calls a potential threat to global security. (Sept. 16) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins